Thus, the CaSR is a therapeutic target with the clinically approved calcimimetics or positive allosteric modulators (PAMs), cinacalcet, etelcalcetide, and upacicalcet, which are used to increase the sensitivity of the CaSR to [Ca2+]o in the parathyroid glands to treat secondary hyperparathyroidism.3, 4. The gene discussed is CASR; the disease is secondary hyperparathyroidism.